The biological activity induced by ligand binding to orthosteric or allosteric sites on a GPCR is mediated by stabilization of specific receptor conformations. In the case of the β 2 adrenergic receptor, these ligands are generally small molecule agonists or antagonists. However, recently a monomeric single domain antibody (nanobody) from the Camelid family was found to allosterically bind and stabilize an active conformation of the β 2 adrenergic receptor (β 2 AR). Here we set out to study the functional interaction of 18 related nanobodies with the β 2 AR to investigate their roles as novel tools for studying GPCR biology. Our studies revealed several sequence related nanobody families with preferences for active (agonist occupied) or inactive (antagonist occupied) receptors. Flow cytometry analysis indicates that all nanobodies bind to epitopes displayed on the intracellular receptor surface; therefore we transiently expressed them intracellularly as "intrabodies" to test their effects on β 2 AR-dependent signaling. Conformational specificity was preserved after intrabody conversion as demonstrated by the ability for the intracellularly expressed nanobodies to selectively bind agonist or antagonist-occupied receptors. When expressed as intrabodies, they inhibited G-protein activation (cyclic AMP accumulation), GRK-mediated receptor phosphorylation, β-arrestin recruitment, and receptor internalization to varying extents. These functional effects were likely due to either steric blockade of downstream effector (Gs, β-arrestin, GRK) interactions or stabilization of specific receptor conformations which do not support effector coupling. Together these findings strongly implicate nanobody-derived intrabodies as novel tools to study GPCR biology.
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Introduction
The conversion of extracellular cues into specific intracellular responses is often mediated by G-protein coupled receptors (GPCRs) and is critical for regulating nearly all physiological processes. For these reasons, GPCRs have become popular therapeutic targets. Even though the GPCR superfamily consists of nearly 800 genes, the general mode of activation and desensitization remains remarkably conserved (Lagerstrom and Schioth, 2008) .
Agonist binding to the orthosteric pocket stabilizes specific receptor conformations leading to the sequential binding of three main protein families: heterotrimeric GTP-binding proteins (G-proteins), G-protein-coupled receptor kinases (GRKs), and β-arrestins. The agonist-induced interaction between receptor and G-protein promotes exchange of GDP for GTP leading to dissociation of the heterotrimeric G-protein subunits (G αβγ ). The free subunits bind to and regulate downstream effectors that commonly generate second messengers such as cAMP (Neves et al., 2002) . Receptor desensitization is initiated by GRK-dependent phosphorylation of residues in the receptor carboxyl-tail and/or in an intracellular loop, which subsequently leads to the recruitment of the multifunctional adaptor protein β-arrestin (Benovic et al., 1987) . Importantly, receptor phosphorylation and β-arrestin binding require specific active receptor conformations.
The coupling of β-arrestin promotes desensitization by sterically blocking further G-protein binding and facilitating receptor internalization by acting as an adaptor for the endocytic machinery (reviewed in (Shenoy and Lefkowitz, 2011) ).
In addition to its role in controlling receptor silencing and trafficking, β-arrestins can also interact with a variety of signaling proteins leading to a unique mechanism of receptor-mediated signal transduction (see ) for a comprehensive review).
The biological activity of most GPCRs is regulated by ligand-mediated stabilization of specific receptor conformations that activate or inhibit downstream signaling events. In the case of the β 2 -adrenergic receptor (β 2 AR), these ligands have been primarily small molecules that bind to the orthosteric binding site. Alternatively, allosteric ligands, which bind sites topographically distinct from the orthosteric binding pocket could be useful in further stabilizing specific receptor conformational states. With particular relevance to the β 2 AR, a single-domain Camelid heavy chain only antibody (nanobody) was recently described that allosterically binds to and stabilizes a specific agonist MOL #89516 activated β 2 AR conformation, which was essential for capturing the active state by crystallography (Rasmussen et al., 2011a) .
More broadly, the use of antibodies as GPCR allosteric modulators is well-founded given their ability to bind a vast array of protein epitopes with high specificity and affinity (reviewed in (Gupta et al., 2008) ). The use of antibodies to fine-tune receptor function in a whole cell context has mainly been restricted to those that bind extracellular epitopes since antibody delivery into the cytoplasm is a challenging endeavor. Intracellular expression of correctly folded antibodies is also very difficult due to the reducing cytoplasmic environment. Although intracellular expression of antibodies (intrabodies) can be achieved by conversion into single chain fragment variants (scFv), antibody function and specificity is often lost (Lo et al., 2008) .
Heavy chain antibodies (HCAbs) from the Camelid family, which lack the light chain polypeptide and first constant domain (CH1), have become of interest since they can be converted into functional single domain containing antibodies (nanobodies) consisting of a single monomeric variable domain (Vincke and Muyldermans, 2012) . Their small size (~12kDa), enhanced stability, high protein yields in bacterial expression systems and high propensity for antigen recognition have made nanobodies very useful tools in protein biology. It has been well documented that nanobodies are capable of binding cryptic epitopes such as those found in the catalytic site of enzymes or ligand binding pockets of receptors (reviewed in (Muyldermans, 2013) ). Furthermore, specific nanobodies have been found to exert agonistic or antagonist effects on their antigens either as orthosteric or allosteric modulators, making them interesting pharmacological tools.
In light of the demonstrated ability of nanobodies to bind distinct conformational states of the β 2 AR and their single-domain nature, we hypothesized that intracellular expression of β 2 AR-specific nanobodies could yield novel tools for the study and regulation of receptor function.
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Maxisorp (NUNC) 96well plates were seeded with 100µL of 10µg/mL purified nanobody overnight at 4 o C. Each new reagent addition was preceded by three 5 minute washes with 300µL wash buffer (Buffer A plus 0.02% n-Dodecyl β-DMaltopyranoside (DDM)). The plate was blocked for 60 min at room temperature (RT) in wash buffer with 3% non-fat milk. Solubilized full-length hβ 2 AR was purified as previously described (Kahsai et al., 2011) and pre-incubated with DMSO, 10µM BI-16707 or ICI-118151 for 30 minutes in buffer A, 0.1% DDM, and 0.5% BSA . Immobilized nanobodies were incubated with 100µL of 0.5µg/mL purified β 2 AR for 90 minutes at RT. Captured β 2 AR was detected using M2-HRP (1:5000) diluted in buffer A, 0.02% DDM, and 0.5% BSA. Antibody was incubated for 1h at RT, plates were subsequently treated with 100µL Ultra-TMB (Pierce), and absorbance was measured at 450nm.
Intrabody and β 2 AR Expression
HEK293 cells were transfected with Fugene (Roche) as described by manufacturer. In brief, sub-confluent HEK293 cells were transfected with a 3:1 ratio of pcDNA-HA-Intrabody and pBK-flag-β 2 AR, respectively, and scraped into lysis buffer (20mM HEPES, 100mM NaCl, 0.5% Maltose-neopentyl glycol (MNG)) 48 hours post-transfection. For β 2 AR deglycosylation, 250 units of PNGase F (New England Biolabs) were incubated with MNG-extracted lysate at room temperature for 1h. Intrabody and β 2 AR expression were assessed by running equivalent total protein on SDS-PAGE and subsequently immunoblotting with HA-HRP (Cell Signaling) or M2-HRP (Sigma) antibodies, respectively. Equal loading was assessed using an anti-Tubulin antibody (Sigma). To determine functional receptor expression, HEK293 cells were transfected as described above, and 48h post-transfection cells were removed from the culture dishes using a 0.5% EDTA solution (Sigma). One well of a 6-well dish was equally divided into four binding reactions and incubated with 30nM [ 3 H]-CGP-12177A plus either assay buffer (DMEM plus 20mM HEPES) or 10µM propranolol (non-specific)
Co-immunoprecipitation
HEK293 cells stably expressing flag-β 2 AR were transfected with pcDNA-HA-Intrabodies and treated with vehicle (DMSO) or 10µM ISO for 15 minutes before scraping cells in MNG-containing lysis buffer (see above). Cells were lysed while rotating at 4 o C for 1h, and insoluble material was separated by centrifugation at 14,000 rpm for 15 minutes.
This article has not been copyedited and formatted. The final version may differ from this version. Flag-β 2 AR was immunoprecipitated via flag-M2 beads (Sigma), and intrabodies were detected using a HA-tag specific antibody.
Flow cytometry
Sf9 cells were infected with a baculovirus encoding N-terminal FLAG-tagged  2 AR construct or a control virus. Three days post-infection, cells were resuspended in assay media (ESF921 media (Expression Systems) containing 2.5mM
CaCl 2 and 0.5% BSA) at a density of 8x10 6 cells/mL and kept at 4°C for the remainder of the experiment. Cells were pre-incubated with DMSO, 1M ICI-118551, or 1M BI-16707. Purified nanobodies were diluted in assay media to a working concentration of 100g/mL, and 20L of cells and 20L of nanobody were combined. Following a 1-hour incubation, cells were harvested, washed 3 times with 100uL assay media, and resuspended in 20L Dylight488-labeled anti-6x His tag antibody (1:500) (Abcam). In parallel, cells that had not been incubated with nanobody were incubated with Dylight488-labeled anti-FLAG M1 antibody (10g/mL). Following a 1-hour incubation, cells were washed 3 times with 100uL assay media and resuspended in 100uL media containing SYTOX AADvanced Dead Cell Stain (Life Technologies). Flow cytometry data were collected on a FACSCantoII flow cytometer (BD Biosciences) and analyzed using CyFlogic software (CyFlo Ltd).
Competition Radioligand Binding Assays
Competition radioligand binding assays were performed on both freshly isolated whole cells and frozen membranes. Briefly, HEK 293 cells expressing the  2 AR were harvested using a 0.05% EDTA solution (Sigma) and collected via centrifugation at 500 x g for 1min. The cells were then washed and resuspended in cold whole cell binding buffer (MEM and 20mM HEPES, pH7.5) prior to the assay. Purified membrane stocks were prepared from  2 ARexpressing Sf9 or HEK293 cells via differential centrifugation. The cells were first washed with cold PBS and then dounce homogenized (100 strokes on ice) in cold homogenization buffer (75mM Tris-HCl, pH7.4, 2mM EDTA, and protease inhibitor cocktail (Roche)). The cell debris was pelleted at 500 x g for 10 minutes at 4 o C, and the microsomal membrane fraction was subsequently recovered from the supernatant via centrifugation at 35,000 x g for 1 hour at 4 o C.
This article has not been copyedited and formatted. The final version may differ from this version. was quantified on a Tri-Carb 2800 liquid scintillation counter (PerkinElmer) following extraction with Lefko Fluor scintillation cocktail (RPI, IL).
[ 3 H]-Methoxyfenoterol Binding Assay
We developed the [ 3 H]-Methoxyfenoterol binding assay to determine the relative amount of  2 AR in active conformations in the absence and presence of nanobodies. We based this approach on the allosteric principle that binding of agonist and transducer to distinct sites on a GPCR reciprocally enhances one another's affinity for the receptor. Thus, agonists possess both low affinity for the uncoupled receptor and high affinity for the transducer-coupled receptor (DeLean and Lefkowitz, 1980; Gurevich et al., 1997) . More generally, this principle applies to other modulators of GPCR function including nanobodies. For example, the binding of Nb80 to the  2 AR increased agonist affinity by 95-fold and was comparable to the 100-fold shift observed with Galphas (Rasmussen et al., 2011a) . Based on the previous report that [ 3 H]-Methoxyfenoterol binds the active  2 AR with ~100-fold greater affinity than the inactive  2 AR (Toll et al., 2012) , we posited that using [and the G αs subunit (Bertin et al., 1994) 
cAMP Assays
A GloSensor cAMP biosensor (Promega) which contains a modified form of firefly luciferase was used to indirectly measure G-protein activation (Fan et al., 2008) . In brief, enzyme complementation as a result of cAMP binding to the GloSensor biosensor results in luminescence following incubation with a luciferase substrate. HEK293 cells were plated at 35K in 96well dishes and 24 hours thereafter each well was transiently transfected with 10ng GloSensor biosensor and 40ng pcDNA-HA-Intrabody using the Fugene6 transfection reagent (Roche). Cells were incubated with GloSensor reagent for 90min at 28 o C 48h post-transfection and then treated with a dose response of ISO for 10min. Luminescence was measured using a NOVOstar microplate reader (BMG Labtech).
Beta-arrestin Recruitment
The recruitment of β-arrestin to the β 2 AR was assessed using the Tango Assay as previously described (Barnea et al., 2008) . To amplify β-arrestin recruitment, the C-terminal tail of β 2 AR was replaced with that of the Vasopressin-2-receptor (β 2 V 2 ) . HEK293-T cells stably expressing a tTA driven luciferase reporter and β-arrestin-2 fused to the Tobacco Etch Virus (TEV) protease were plated at 35K in 96-well dishes and transiently transfected with 40ng pcDNA-HA-Intrabody and 10ng of β 2 V 2 followed by a TEV protease site and tTA transcription factor. Upon agonist stimulation, recruitment of β-arrestin-TEV leads to cleavage of the tTA fused to β 2 V 2 resulting in nuclear translocation and transcription of the luciferase reporter. Cells were treated with a dose response of ISO 36h
post-transfection and the Bright-Glo luciferase substrate (Promega) was added 16h thereafter.
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Results:
To test whether intracellular expression of nanobodies (Nbs) could be used as novel tools to modulate receptor function, we set out to characterize a panel of nanobodies previously found to specifically bind the β 2 AR. In brief, these nanobodies were obtained by immunizing one llama (Lama glama) with β 2 AR reconstituted in lipid vesicles bound to the high affinity agonist BI-167107 (Rasmussen et al., 2011a) . Sequence alignment placed the18 unique nanobody clones into four distinct families (A, B, C, and MISC) based on CDR3 conservation ( fig 1A) . Nanobodies from all four families were subsequently purified from E. coli and tested in an ELISA assay to characterize their propensity to bind agonist or antagonist-occupied β 2 AR. Consistent with the demonstrated ability for Nb80 to bind activated β 2 AR (Rasmussen et al., 2011a) , nanobodies in family B showed a clear preference for agonist (BI-167107)-occupied β 2 AR when compared to the inverse agonist (ICI-118551)-occupied β 2 AR ( fig 1B) . Similar results were obtained for Nb families C and MISC, although their preferences for the activated receptor were more variable ( fig 1B) . Importantly, the control nanobody (Nb30) that was obtained in a separate immunization using a different antigen did not recognize the β 2 AR regardless of ligand occupancy.
To confirm that these nanobodies are truly stabilizing an active receptor state and not just a unique conformation specific to BI-167107, we measured Nb80 binding to receptor by ELISA in the presence of various β 2 AR antagonists and agonists. Nb80 robustly bound to agonist (BI-167107, Isoproterenol (ISO), and Formoterol (For)) occupied β 2 AR, but this binding was significantly reduced or eliminated in the presence of a partial agonist Salbutamol (SalB) or antagonists (ICI-118551, Carazolol (Caraz)), respectively (Supplemental Figure 1) . Although family A Nbs could bind to the active BI-167107-occupied β 2 AR, they clearly favored the inactive ICI-118551-occupied β 2 AR ( fig 1B) . These data indicate that all nanobodies screened have a preference for binding specific active (families B, C and MISC) or inactive (family A) β 2 AR conformations. Moreover, the observation that occupancy of the β 2 AR by BI-167107 or ICI-118551 increased Nb binding suggests they bind to an allosteric site distinct from the orthosteric binding pocket.
We next assessed the ability of Nbs to stabilize active or inactive β 2 AR conformations by measuring their respective abilities to increase or decrease binding of a radiolabeled β 2 AR agonist, [ 3 H]Methoxyfenoterol (Toll et al., 2012) . It has long been established that allosteric transducers like G proteins and β-arrestins promote high affinity agonist binding by stabilizing active receptor conformations (DeLean and Lefkowitz, 1980; Williams and Lefkowitz, 1977 (fig 2) . This is consistent with their preferences for binding active β 2 AR conformations ( fig   1B) . By contrast, family A nanobodies moderately but significantly decreased [3H]-Methoxyfenoterol binding, which was in good agreement with their preference for the inactive receptor ( fig 1B) . Taken together, these data suggest that family A nanobodies stabilize inactive β 2 AR conformations, whereas families B, C, and MISC stabilize active β 2 AR conformations.
We next used flow cytometry and SF9 insect cells expressing flag-β 2 AR to determine whether the nanobodies bound intracellular or extracellular β 2 AR epitopes. As a consequence of baculovirus infection, we observed permeable and non-permeable cells expressing flag-β 2 AR at similar levels as shown by flag-antibody staining (fig 3 top panels) .
However, all nanobodies from the MISC group and representative nanobodies (see fig S2 for fig 4C) . Taken together, these data demonstrate that nanobodies can be expressed as intrabodies and that their remarkable selectivity for specific receptor conformations is conserved.
Next, all nanobodies that stabilized an active β 2 AR conformation (families B, C, and MISC, fig1) were tested as intrabodies for their potential to modulate β 2 AR-dependent signaling. Intrabody expression varied extensively, but these differences had little effect on β 2 AR expression ( fig 5A, B, C left panel) . G-protein activation and β-arrestin recruitment were measured in HEK293 cells using luminescence-based strategies (see Methods for details). Using these assays we
found that approximately half of the intrabodies had significant yet variable inhibitory effects on G-protein activation and β-arrestin recruitment ( fig 5A , B, C middle and right panels). The reductions in the maximal effect (E max ) of ISO in both G-protein activation (cAMP) and β-arrestin recruitment induced by intrabody expression were calculated and summarized in figure 5D .
When tested in the same assays, the majority of intrabodies that stabilized an "inactive" 6D) . This suggested that the large inhibitory effects of these family A nanobodies on receptor signaling therefore may be due to stabilization of specific receptor conformations or a reduction in receptor expression, or a combination of both factors.
Interestingly, we observed that several members of each nanobody family were more effective at inhibiting β-arrestin recruitment than cAMP generation ( fig 5D and 6D) . In order to rule out the possibility that the β-arrestin recruitment assay was more sensitive to inhibition than the cAMP assay, we measured the level of assay amplification in both assays. As shown in Supplemental figure 4, partial agonists elicited similar submaximal responses for both β-arrestin recruitment and cAMP accumulation, suggesting that both assays were equally coupled. Thus, variations in assay amplification could not explain the differential inhibitory effects of intrabodies such as Ib71.
This article has not been copyedited and formatted. The final version may differ from this version. Given its high expression and marked inhibitory effects on both G-protein activation and β-arrestin recruitment assays (fig 5) , we focused on Ib71 to further investigate the effects of intrabody expression on β 2 AR-dependent signaling.
Consistent with our earlier findings, Ib71had no effect on receptor expression (fig 7A) , selectively coimmunoprecipitated with flag-β 2 AR after ISO treatment (fig 7B) , and stabilized a β 2 AR high affinity state as assessed by whole cell competition binding experiments ( fig 7C) . Since β-arrestin recruitment is known to be highly dependent on GRK phosphorylation of the β 2 AR C-terminal tail, we set out to determine if GRK-mediated receptor phosphorylation is altered in the presence of Ib71. As shown in figure 7D , dose-dependent phosphorylation of Serine 355 and Serine356
(Ser 355/356) (canonical GRK5/6 phosphorylation sites) on the β 2 AR was strongly inhibited by Ib71 in comparison to Ib30 or the empty vector control ( fig 7D) . To further validate the inhibition of β-arrestin recruitment by Ib71, we conducted β 2 AR-βArr crosslinking and GFP-βArrestin2 recruitment experiments in live cells. Cross-linking studies demonstrated that Ib71 markedly decreased the amount of β-arrestin recruited to the β 2 AR after isoproterenol treatment when compared to the empty vector or Ib30 controls ( fig 7E) . Furthermore, Ib71, but not Ib30, blocked the recruitment of GFP-β-arrestin2 to immunoreactive puncta containing the β 2 AR following ISO stimulation as assessed by confocal microscopy ( fig 7G) . Taken together, these data demonstrate that Ib71 is a powerful inhibitor of β-arrestin recruitment to the β 2 AR, presumably exerting this effect by blocking receptor phosphorylation.
Discussion
It has been repeatedly demonstrated that targeting the biological activity of GPCRs has tremendous therapeutic potential given their indispensable roles in regulating a vast array of physiological and pathological processes. While most studies have focused on using orthosteric ligands, the use of allosteric modulators to further fine-tune receptor function has become of recent interest (Conn et al., 2009; Wang and Lewis, 2013; Wang et al., 2009 ). Herein we explored the ability of a panel of closely related single-domain Camelid heavy chain antibodies (nanobodies) to allosterically target and stabilize distinct agonist-bound ('active') and antagonist-bound ('inactive') β 2 AR conformations.
Our studies uncovered four families of nanobodies with differing abilities to stabilize active or inactive β 2 AR conformations. Subsequent conversion of these nanobodies to intrabodies revealed a variety of effects on cAMP accumulation and β-arrestin recruitment, supporting their utility as novel tools to study GPCR biology.
One of the major goals of this study was to explore the role of nanobodies in modulating receptor function by expressing them as intrabodies in mammalian cells. Unlike the case for traditional antibodies and antibody fragments (Fabs) which require proper folding of multiple domains, we hypothesized that the unique single domain nature of nanobodies would allow for their functional expression in the reducing cytoplasmic environment. We found that the active state nanobody-derived intrabodies are selectively recruited to the β 2 AR upon agonist treatment resulting in inhibition of both G-protein activation and β-arrestin recruitment. Unlike modulators that bind linear epitopes, the remarkable selectivity of these intrabodies for specific β 2 AR conformations may reduce the probability of having offtarget effects within the cell. Furthermore, in addition to directly modulating receptor function, intrabodies were recently used to monitor the activation state of the β 2 AR and its cognate G protein in live cells (Irannejad et al., 2013) . Taken together, the use of intrabodies as tools to study GPCR biology will likely extend well beyond this study.
There are likely many different mechanisms by which these intrabodies can inhibit β 2 AR signaling. Since several studies have recently highlighted the ability of an agonist bound GPCR to reside in an array of conformations (Ghanouni et al., 2001; Kahsai et al., 2011; Yao et al., 2006) , it is plausible that this heterogeneity would lead, to nanobodies which stabilize a variety of distinct conformations. Therefore, stabilization of specific conformations that are This article has not been copyedited and formatted. The final version may differ from this version. not conducive to effector coupling would result in inhibition of receptor signaling. This is likely the mode of inhibition seen with intrabodies which stabilize an inactive receptor state (family A). However, we cannot rule out the possibility that other intrabody families may stabilize specific conformational states that fail to couple to downstream effectors.
Secondly, intrabody recruitment to the receptor following agonist stimulation could sterically block the binding of Gprotein and/or β-arrestin. This is most certainly the case with Ib80 since recent crystallographic findings demonstrate that the binding epitope and β 2 AR conformation stabilized by both Nb80 and the heterotrimeric G-protein complex are nearly identical (Rasmussen et al., 2011a; Rasmussen et al., 2011b) . Although the receptor binding interface between β-arrestin and nanobodies other than Nb80 is not yet known, steric occlusion could explain the inhibitory effects of intrabodies from families B, C, and MISC.
Nanobodies in family B, C and MISC were shown to stabilize an active receptor conformation ( fig 1B and 2 ), which could result in chronic receptor activation in the absence of agonist leading to desensitization and/or receptor internalization. Given that we did not observe any decreased levels of receptor expression upon intrabody expression ( fig 4A-B, 5A and 7A) together with the lack of binding of Ib80 or Ib71 to the β 2 AR in the absence of agonist ( fig 4C, 7B), we find this possibility unlikely. Additionally, since the β 2 AR can also couple to Gi (Daaka et al., 1997) , we cannot rule out the possibility that decreases in cAMP levels seen here are mediated by modulation of this signaling pathway.
Additional studies will be required to delineate the potential mechanisms by which these nanobodies regulate cAMP production and β-arrestin recruitment.
The discovery that β-arrestin signaling can occur independently of G-protein activation has led to consideration of the possibility that specific receptor signaling arms can be pharmacologically isolated, a concept which is referred to as 'functional selectivity' or 'biased agonism' (reviewed in (Reiter et al., 2012) ). Perhaps the best example of this phenomenon is observed with the angiotensin type 1 receptor where two biased agonists, SII (Sar 1 , Ile 4 , Ile 8 -angiotensin II) and most recently TRV027, selectively stimulate β-arrestin dependent signaling in the absence of Gq-protein activation (Violin et al., 2010; Wei et al., 2003) . Our findings suggest that numerous intrabodies have a disproportionate effect on inhibition of G-protein activation or β-arrestin recruitment implying that they may be partially biased (figs 5 and 6). However, since these two signaling arms were measured using different assay platforms, the quantification of such intrabody bias will need to be further investigated given the confounding variables of receptor, intrabody, and effector expression. Such analysis will likely require the development of novel assays to quantitatively measure Gprotein activation and β-arrestin recruitment in the same cells. Nonetheless, despite the fact that our β-arrestin recruitment assay utilized over-expression of both β 2 AR and β-arrestin (compared to endogenous receptor and G-protein in cAMP assays), many of the intrabodies (i.e. Nb63, 71 and 72) were still capable of inhibiting β-arrestin recruitment to a greater extent than G-protein activation. Given the current findings, we cannot determine whether this biased inhibition is due to enhanced steric blockade of β-arrestin or stabilization of specific receptor conformations less conducive to β-arrestin coupling in comparison to G-protein. Additionally, several studies have now demonstrated pre-coupling of receptor and G-protein which could sterically hinder nanobody binding, resulting in the observed differential inhibition of β-arrestin recruitment and G-protein activation (Nobles et al., 2005; Qin et al., 2011) . Furthermore, intrabodymediated inhibition of β-arrestin recruitment may also be attenuated due to diminished levels of GRK-dependent receptor phosphorylation. Further work will be required to delineate the detailed molecular mechanisms governing this potential bias.
Targeting the biological functions of many receptors and signaling pathways in a cell-type specific manner in vivo remains a challenging endeavor. More specifically, generating cell-type specific knockouts can be quite difficult, and localized or global antagonist treatments can have a variety of off-target effects which make data interpretation problematic, although considerable advances have recently been made using RASSL and DREADD technologies (Conklin et al., 2008) . In this context, intrabody expression driven by cell-type specific promoters may provide a novel strategy to examine the contribution of particular receptors and signaling pathways to regulating numerous physiological and pathological processes. Additionally, the discovery of intrabodies that bias signaling may also be useful in dissecting the influence of specific signaling arms to downstream receptor-mediated events in vivo. Given the recent discovery of a nanobody that stabilizes the active state of the M2 muscarinic acetylcholine receptor (Kruse et al., 2013) , the use of nanobodies to modulate receptor function will likely extend well beyond this study. Although we have focused on the use of allosteric intrabodies to manipulate GPCR function, these reagents could also conceivably be used to modulate other intracellular targets. Indeed, nanobodies have been described that allosterically activate or inhibit the This article has not been copyedited and formatted. The final version may differ from this version. catalytic function of specific enzymes (Barlow et al., 2009; Oyen et al., 2011; Saerens et al., 2004) . Furthermore, a nanobody that inhibits clostridium botulinum neurotoxin proteases maintained its antagonist properties when expressed as an intrabody in neuronal cells (Tremblay et al., 2010) . The recent development of small molecule or peptide reagents that facilitate efficient delivery of biologically active proteins across cell membranes could be used to deliver intrabodies, thereby extending their use to acutely regulate protein function in live cells (Milletti, 2012) . Although all nanobodies discussed herein bind to intracellular receptor epitopes, the identification of nanobodies that modulate receptor function by binding to extracellular epitopes as orthosteric or allosteric ligands may prove to be very useful therapeutic agents.
In conclusion, our data demonstrate that nanobody-derived intrabodies function as novel regulators of β 2 ARdependent G-protein activation and β-arrestin recruitment. These innovative reagents will undoubtedly be powerful tools for furthering our understanding of GPCR biology.
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Fig 2: Nanobodies allosterically stabilize active or inactive β 2 AR conformations: SF9 insect cell membranes expressing flag-β 2 AR were incubated with 4nM [ 3 H]-Methoxyfenoterol and 1µM nanobody (Nb) in the absence (total binding) or presence of 10µM Propranolol (non-specific). Specific binding was determined by subtracting non-specific from total binding and normalized relative to Nb80. The absence of nanobody (---) and Nb30 were negative controls. Ttests were performed to determine significance between each nanobody and (---) ( *p<0.05).
Fig 3:
Nanobodies bind specifically to intracellular epitopes of the β 2 AR. SF9 insect cells were infected with a baculovirus encoding flag-β 2 AR resulting in cell populations that were partially permeabilized due to viral infection. β 2 AR-expressing cells were pre-incubated with 1µM ICI-118551 (Family A nanobodies) or 1µM BI-167107 (Families B, C, and MISC). Binding of purified His-tagged nanobodies to cells was detected with a DyLight488-labeled anti-6x His antibody. Flag M1 antibody was labeled with DyLight488. Singlet cells were gated into intact and permeable populations based on staining with SYTOX AADvanced Dead Cell Stain. with the agonist isoproterenol (ISO) for 15 minutes, and then solubilized in lysis buffer. Flag-β 2 AR was immunoprecipitated (IP) using flag-beads, the eluate was subjected to SDS page, and intrabody detected using an HA antibody.
Fig 5: Regulation of β 2 AR functions by "active" state stabilizing intrabodies. Receptor expression (left panels), Gprotein-mediated cAMP levels (GloSensor) (middle panels) and β-arrestin recruitment (Tango Assay) (right panels) was measured for intrabody family B (A), C (B) and MISC (C). A-C) Left Panels: Immunoblot analysis of HEK293 cells transiently transfected with flag-β 2 AR and the indicated HA-Intrabody (Ib). Tubulin was used to ensure equal total protein loading. A-C) Middle Panels HEK293 cells were transfected with the GloSensor cAMP biosensor (Promega) and pcDNA empty vector or individual HA-intrabodies, stimulated with a dose response of isoproterenol (ISO), and luminescence measured 10min thereafter. Data were analyzed using Graphpad Prism program with sigmoidal dose response curve fit and normalized to 100% pcDNA empty vector. A-C) Right Panels: HEK293T cells stably expressing β-arrestin2 fused to the Tobacco Etch Virus (TEV) protease and a tTA transcription factor driven luciferase reporter were transiently transfected with β 2 AR fused to the tTA transcription factor but separated by a TEV cleavage site and the indicated HA-intrabody. Cells were stimulated with a dose response of isoproterenol, and luminescence was measured 16h thereafter. Data were normalized as described in C. D) The maximal response (E max ) for cAMP and β-arrestin following isoproterenol treatment in presence of the indicated intrabody as determined by non-linear regression analysis. Data were normalized to 100% pcDNA. T-tests were used to compare each intrabody to pcDNA control (*p<0.05), underlined * denotes significance between B max of Glosensor and Tango assays for each individual intrabody. The effects of intrabody family A on expression of β 2 AR (A), G-protein activation (B) and β-arrestin recruitment (C) were analyzed as described in figure 4. D) The maximal response (E max ) for cAMP and β-arrestin following isoproterenol treatment in presence of indicated intrabody as determined by non-linear regression analysis. Data was normalized to 100% pcDNA. T-tests were used to compare each intrabody to pcDNA control (*p<0.05), underlined * denotes significance between B max of Glosensor and Tango assays for each individual intrabody. 3 H]-CGP-12177A and a dose response of isoproterenol. D) HEK293 cells transiently expressing flag-β 2 AR and pcDNA, Ib30, or Ib71 were stimulated with a dose response of isoproterenol and analyzed for GRK-dependent phosphorylation of serine 355/6. E) Whole cell crosslinking of βArr1/2 with flag-β 2 AR in HEK293 cells in presence of pcDNA, Ib30, or Ib71 after stimulation with 10µM isoproterenol. F) U2OS cells were transiently transfected with flag-β 2 AR, GFP-β-arrestin2, and Myc-tagged Ib30 or Ib71 and βArr recruitment and receptor internalization was visualized using immuno-staining and confocal microscopy.
